Literature DB >> 28831408

Shotgun metagenomic data on the human stool samples to characterize shifts of the gut microbial profile after the Helicobacter pylori eradication therapy.

Eugenia A Boulygina1, Maria I Markelova1, Dilyara R Khusnutdinova1, Maria N Siniagina1, Sergey Yu Malanin1, Rustam A Abdulkhakov2, Sayar R Abdulkhakov1,2, Vladislav M Chernov1, Tatiana V Grigoryeva1.   

Abstract

The shotgun sequencing data presented in this report are related to the research article named "Gut microbiome shotgun sequencing in assessment of microbial community changes associated with H. pylori eradication therapy" (Khusnutdinova et al., 2016) [1]. Typically, the H. pylori eradication protocol includes a prolonged two-week use of the broad-spectrum antibiotics. The presented data on the whole-genome sequencing of the total DNA from stool samples of patients before the start of the eradication, immediately after eradication and several weeks after the end of treatment could help to profile the gut microbiota both taxonomically and functionally. The presented data together with those described in Glushchenko et al. (2017) [2] allow researchers to characterize the metagenomic profiles in which the use of antibiotics could result in dramatic changes in the intestinal microbiota composition. We perform 15 gut metagenomes from 5 patients with H. pylori infection, obtained through the shotgun sequencing on the SOLiD 5500 W platform. Raw reads are deposited in the ENA under project ID PRJEB21338.

Entities:  

Keywords:  Antibiotics; Eradication; Helicobacter pylori; Human gut microbiota

Year:  2017        PMID: 28831408      PMCID: PMC5554923          DOI: 10.1016/j.dib.2017.07.070

Source DB:  PubMed          Journal:  Data Brief        ISSN: 2352-3409


Specifications Table Value of the data The data allow researchers to evaluate changes in the taxonomic and functional composition of the human gut microbiota, which is associated with the use of amoxicillin and clarithromycin. Since the data include the metagenome profile at the 3rd time point (several weeks after the end of H. pylori eradication), it is possible to make assumptions about the reversibility/irreversibility of therapy-related changes. The data can be used to estimate the distribution of antibiotic resistance genes in the genetic pool of the gut microbiota after H. pylori eradication therapy. Using this data one can describe the general trends of the microbial composition variation caused by antibiotics and predict possible side effects. The data can be used to detect the genetic markers of dysbiosis and to design a minimally invasive PCR diagnostic system.

Data

The data represent the result of metagenomic shotgun-sequencing of human gut microbiota at 3 time points: before the H. pylori eradication therapy, immediately after 2 weeks of therapy and several weeks after the treatment. The dataset contains 15 metagenomic samples in raw reads format with 30.4 ± 10.7 mln of reads per sample (mean ± SD). These data together with those described in [2] were involved in the study devoted to the gut microbiome changes caused by antimicrobial therapy [1]. These data together with those described in [2] were involved in the study devoted to the gut microbiome changes caused by antimicrobial therapy [1]. Detailed description of samples is given in Table 1.
Table 1

Description of samples. “Time point” column shows the time of sample collection: “1” means at the start of the therapy, “2” – immediately after therapy, “3” – several weeks after therapy.

Patient IDGenderDiagnosisSample IDTime point
1MaleGastroesophageal reflux disease1HP1
2HP2
3HP3 (3.5 weeks after treatment)
2MaleChronic gastroduodenitis26HP1
27HP2
28HP3 (4 weeks after treatment)
3FemaleGastroesophageal reflux disease41HP1
42HP2
43HP3 (11 weeks after treatment)
4FemaleChronic gastroduodenitis31HP1
53HP2
54HP3 (4 weeks after treatment)
5MaleGastroesophageal reflux disease63HP1
64HP2
65HP3 (2.5 weeks after treatment)
Description of samples. “Time point” column shows the time of sample collection: “1” means at the start of the therapy, “2” – immediately after therapy, “3” – several weeks after therapy.

Experimental design, materials and methods

Sample collection

Fifteen stool samples from 5 patients with symptoms of stomach and/or duodenum disease and Helicobacter pylori detected by endoscopy were taken for analysis. According to the Maastricht V Consensus and recommendations of Russian Gastroenterological Association, patients had been prescribed a two-week eradication therapy consisted of amoxicillin (1000 mg bid), clarithromycin (500 mg bid) and proton pump inhibitors at a standard dose accompanied by bismuth subsalicylate (240 mg bid) [3]. Samples were collected in the Polyclinic Department of the Republican Clinical Hospital #2 (Kazan). The study was approved by the Local Ethics Committee of the Kazan Federal University. Prior written informed consent was obtained from all patients.

Sample preparation and sequencing

Fecal samples were collected in the individual plastic containers, avoiding contamination with urine or toilet tissue. 10–20 g of samples were instantly frozen with subsequent storage at −20 °C, or were used for DNA extraction immediately after sampling. Total DNA (5 μg) from fecal samples was extracted using the Purelink Genomic DNA Extraction Kit (Invitrogen, USA). Metagenomic single-end library preparation and shotgun sequencing on SOLiD 5500 W platform was performed according to the recommendations of the manufacturer (LifeTechnologies, USA). The resulting color-spaced reads with length of 50 bp were converted to the base-space format.
Subject areaBiology
More specific subject areaMetagenomics
Type of dataDNA sequences
How data was acquiredShotgun DNA sequencing using SOLiD 5500 W platform
Data formatRaw
Experimental factorsTotal DNA extraction from stool samples
Experimental featuresSingle-end read libraries were created from 5 μg of total DNA. Shotgun metagenomic sequencing was performed on SOLiD 5500 W platform according to the recommendations of the manufacturer.
Data source locationKazan, Russian Federation
Data accessibilityData are available from ENA under project accession number PRJEB21338
  2 in total

1.  Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report.

Authors:  P Malfertheiner; F Megraud; C A O'Morain; J P Gisbert; E J Kuipers; A T Axon; F Bazzoli; A Gasbarrini; J Atherton; D Y Graham; R Hunt; P Moayyedi; T Rokkas; M Rugge; M Selgrad; S Suerbaum; K Sugano; E M El-Omar
Journal:  Gut       Date:  2016-10-05       Impact factor: 23.059

2.  Data on gut metagenomes of the patients with Helicobacter pylori infection before and after the antibiotic therapy.

Authors:  Oksana E Glushchenko; Andrei E Samoilov; Evgenii I Olekhnovich; Boris A Kovarsky; Alexander V Tyakht; Alexander V Pavlenko; Vlad V Babenko; Andrei K Larin; Elena S Kostryukova; Maja V Malakhova; Elena N Ilina; Rustem A Abdulkhakov; Dilyara I Safina; Tatiana V Grigoryeva; Sayar R Abdulkhakov; Vadim M Govorun
Journal:  Data Brief       Date:  2017-01-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.